Rigel Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 28.13 million compared to USD 22.41 million a year ago. Net loss was USD 5.69 million compared to USD 19.04 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.11 a year ago.
For the nine months, revenue was USD 81.09 million compared to USD 68.96 million a year ago. Net loss was USD 25.83 million compared to USD 59.97 million a year ago. Basic loss per share from continuing operations was USD 0.15 compared to USD 0.35 a year ago.